ResMed Inc. (RMD) Market Cap & Valuation Ratios
ResMed Inc. (RMD) has a market cap of $36.5B, a trailing P/E of 24.2 and a price-to-sales ratio of 6.5, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RMDResMed Inc.Follow RMD — free
—
Price chart with a free account
- Market cap
- 36.5B
- P/E TTM
- 24.2
- Dividend yield
- 0.9%
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Peers
medical instruments & supplies · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| RMD | 36 | 24.2 | 6.3 | 17.1 | 4.5% | +10% | 33% | 27% |
| ISRG | 157 | 54.8 | 13.2 | 37.1 | 2.3% | +20% | 28% | 20% |
| BDX | 54 | 59.9 | 3.2 | 13.9 | 4.9% | +8% | 12% | 6% |
| MDLN | 45 | — | 1.8 | 19.3 | 3.4% | +11% | 6% | 7% |
| WST | 28 | 50.2 | 8.2 | 31.8 | 1.6% | +12% | 20% | 20% |
| SOLV | 15 | — | 2.3 | 7.4 | -0.8% | -0.9% | 25% | 17% |
| BAX | 13 | — | 1.8 | 30.0 | 6.2% | +5% | -2% | -2% |
| AVTR | 12 | — | 2.3 | 128.6 | 3.9% | -2% | -5% | -3% |
| COO | 12 | — | 3.3 | 15.1 | 5.8% | +5% | 13% | 3% |
| ALGN | 11 | 26.9 | 2.4 | 12.3 | 5.8% | +4% | 13% | 13% |
| RGEN | 10.0 | 242.4 | 12.4 | 67.8 | 1.1% | +16% | 8% | 3% |
| Median of these 10 | 54.8 | 2.8 | 24.6 | 3.7% | +7% | 12% | 6% |
P/E 24.2 vs. a peer median of 54.8; EV/Sales 6.3 vs. 2.8. RMD's own P/E sits at the 18th percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesMDLN and SOLV and BAX and AVTR and COO have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
ResMed Inc. — questions
- What is ResMed Inc.'s market cap?
- $36.5B.
- What is ResMed Inc.'s P/E ratio?
- 24.2 on trailing twelve-month earnings to 2026-06-30.
- What is ResMed Inc.'s price-to-sales ratio?
- 6.5.
Every figure on this page comes from ResMed Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.